Clinical Report: Reduced-Dose Radiation Shows Durable Control
Overview
A cohort study found that a deintensified 60-Gy radiotherapy regimen resulted in low long-term locoregional recurrence rates among selected patients with HPV-associated oropharyngeal carcinoma. The study demonstrated a 5-year locoregional recurrence rate of 3.4% and overall survival of 92.4%.
Background
The management of HPV-associated oropharyngeal carcinoma (OPC) is evolving, with ongoing discussions about the potential for deintensified treatment regimens. Standard treatment typically involves higher doses of radiotherapy, which can lead to significant side effects. Understanding the efficacy and safety of reduced-dose regimens is crucial for optimizing patient outcomes and minimizing treatment-related morbidity.
Data Highlights
Outcome
Rate (%)
95% CI
Locoregional recurrence
3.4
1.1–5.8
Progression-free survival
86.5
82.1–91.0
Overall survival
92.4
89.0–96.0
Distant recurrence
7.3
N/A
Key Findings
5-year locoregional recurrence rate was 3.4% among patients treated with 60 Gy.
Overall survival at 5 years was 92.4%, indicating favorable long-term outcomes.
Progression-free survival was 86.5%, with nodal stage being the only independent factor associated with progression-free survival events.
46.2% of recurrences occurred more than 2 years after treatment, suggesting the need for prolonged surveillance.
Among lower-risk patients treated with radiotherapy alone, the 5-year progression-free survival was 93.8% with no locoregional recurrences.
Clinical Implications
The findings support the consideration of reduced-dose radiotherapy in carefully selected patients with HPV-associated OPC, particularly those with lower-risk disease. Clinicians should engage in informed discussions with patients about the potential benefits and risks of deintensified treatment approaches.
Conclusion
This study provides evidence that a modest dose deintensification of radiotherapy can achieve durable locoregional control in HPV-associated OPC, although it does not alter the current standard of care.
April is Head and Neck Cancer Awareness Month, highlighting a diverse group of diseases that account for nearly 5% of all cancers in the United States.
This quality improvement project found that using a distress screening tool for head and neck cancer patients who were 2 or more years post-treatment led to an increased number of referrals for psychosocial needs.
